Holiday Hours

With the exception of Inova hospitals, Inova Emergency Care and Inova-GoHealth Urgent Care, all Inova outpatient offices will be closed for the New Year's Day holiday – Wednesday, Jan. 1.

Some Inova care sites have additional closures for the holidays, which will be noted on the relevant location pages. 

Call: 571-472-2972
Meet our team Contact us

Inova Cardio-Oncology Program

Inova Schar Heart and Vascular has partnered with Inova Schar Cancer to establish a cardio-oncology program to help patients avoid cardiotoxicity from chemotherapy and radiation treatments. Cardiovascular effects from cancer treatment can develop years later and are the second leading cause of death among cancer survivors. Improvements in early detection and cancer treatments have resulted in an increasing number of long-term cancer survivors, which increases the importance of involving a cardiologist before, during and following cancer treatments to help avoid negative cardiovascular effects.

Our approach

This program capitalizes on an emerging field within cardiology by examining the side effects of cancer therapies on the heart. Increasingly, research shows heightened risks for various heart conditions such as cardiomyopathy or heart failure during and after cancer treatment. Inova's cardio-oncology physicians have developed standardized protocols to prevent, detect, monitor, and treat cardiotoxicity.

Who qualifies for this program?

The program initially began as a pilot for patients with breast cancer and has now expanded to other cancer types. New cancer patients receiving certain higher risk treatments will undergo cardiovascular risk stratification, an ongoing process of assigning patients an individualized risk status. The physicians involved in the initiative have developed standardized protocols for prevention, detection and monitoring during treatment and how to treat cardiotoxicity if it occurs.

These protocols include:

  • Monitoring patients using echocardiograms with strain imaging (to assess early left ventricular dysfunction) and cardiac biomarker blood testing
  • Performing preoperative cardiovascular assessment before cancer surgery
  • Determining cardiotoxicity risk depending on prescribed chemotherapy and radiotherapy, altering/substituting therapies as needed
  • Screening for signs of previous cardiovascular disease
  • Implementing guideline-directed medical therapy for patients with preexisting left ventricular dysfunction or cases that develop during treatment
  • Discussing the importance of exercise with patients who are undergoing cancer treatment
  • Initiating multidisciplinary discussions with patients’ oncologists regarding monitoring and treatment

Contact us